IDEX - IDEX

Ideanomics Stock (NASDAQ:IDEX), Trade Ideas

Ideanomics

Ideanomics Inc is an American multinational company engaged in accelerating the commercial adoption of electric vehicles. The company conducts its operations in one segment with three business units; Ideanomics Mobility's focus is electric vehicles, including mid and last-mile delivery trucks and vans, tractors, and two-wheelers. There are five operating companies within the Ideanomics Mobility business unit: VIA, Energica, Solectrac, United States Hybrid, and Tree Technologies, Ideanomics Energy's focus is charging and energy-related products and services, and Ideanomics Capital's focus is providing financing support for the Company's Mobility and Energy business units. Geographically, the company operates in North America, Asia, and Europe.

News

Penny Stocks

IDEX

Ideanomics Inc (NASDAQ: IDEX) shares are trading lower by 9.1% to $2.44 Thursday afternoon, despite a lack of company-specific news for the session. The stock is falling amid weakness in EV- and EV-related companies after Tesla Inc reported worse-than-expected third-quarter financ

What&#39;s Going On With Ideanomics (IDEX) Stock?

Ideanomics Inc (NASDAQ: IDEX) shares are trading lower by 8.8% to $1.92 Monday morning, despite a lack of company-specific news for the session.

What&#39;s Going On With Ideanomics Stock?

Ideanomics Inc (NASDAQ: IDEX) shares are trading lower by 9.7% to $2.10 Friday afternoon. This decline follows the company&#39;s recent implementation of a 1-for-125 reverse stock split. Over the past month, Ideanomics shares have experienced a significant decrease, falling approximately 74%.

Ideanomics Stock (IDEX) Hit A New All-Time New Today: What&#39;s Going On?

Ideanomics Inc

IDEX - United States Dollar

INDUSTRIA DE DISENO NEW by Industria de Diseno Textil Inditex SA

Industria De Diseno Textil SA

INDUSTRIA DSNO UNSP/ADR by Industria de Diseno Textil Inditex SA

IDEX BIOMETRICS ASA NEW by IDEX Biometrics ASA

IDEX Biometrics ASA

IDEX Biometrics ASA ADR

IDEX Corp

IDEXX Laboratories Inc

TD Cowen analyst Paul Gallant maintains T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) with a Buy and lowers the price target from $204 to $202.

Price Target

Analyst Ratings

TMUS

TD Cowen Maintains Buy on T-Mobile US, Lowers Price Target to $202

Oppenheimer analyst Noah Kaye maintains Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) with a Outperform and raises the price target from $221 to $228.

Oppenheimer Maintains Outperform on Waste Management, Raises Price Target to $228

WIIM

XPEV

XPeng shares are trading higher amid overall strength in Chinese stocks.

TD Cowen analyst John Blackledge maintains Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) with a Hold and raises the price target from $11 to $14.

SNAP

TD Cowen Maintains Hold on Snap, Raises Price Target to $14

TBBB

Tiendas 3B shares are trading higher following Q4 financial results.

Oppenheimer analyst Tyler Batory maintains Tri Pointe Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPH#NYSE">TPH</a>) with a Outperform and raises the price target from $41 to $46.

Oppenheimer Maintains Outperform on Tri Pointe Homes, Raises Price Target to $46

IBRX

ImmunityBio shares are trading higher after the company on Thursday announced overall survival results in its QUILT 3.055 study.

Shares of Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) fell sharply during Friday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/AON/earnings">quarterly financial results</a>.
Aon posted adjusted earnings of $5.66 per share, missing market estimates of $5.91 per share. The company's sales came in at $4.070 billion versus expectations of $4.126 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Aon shares dipped 7.4% to $283.19 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Biodexa Pharmaceuticals Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares jumped 73.3% to $1.2475 after the company entered an exclusive license agreement with Rapamycin Holdings for the rights to eRapa.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) gained 63% to $0.0845.</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares gained 55% to $2.01 after dipping 16% on Thursday.</li>
<li>Universal Logistics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULH#NASDAQ">ULH</a>) surged 45.2% to $47.76 after the company reported better-than-expected first-quarter financial results.</li>
<li>Focus Universal Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCUV#NASDAQ">FCUV</a>) jumped 40% to $0.3967 after the company announced board approval for the spin-off of Lusher.</li>
<li>BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>) gained 37% to $2.68.</li>
<li>Concord Medical Services Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) gained 29% to $0.6502. Concord Medical filed 2023 annual report on Form 20-F.</li>
<li>Exponent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPO#NASDAQ">EXPO</a>) shares climbed 28.5% to $102.41 after the company reported better-than-expected first-quarter financial results.</li>
<li>Skillsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKIL#NYSE">SKIL</a>) climbed 26.4% to $8.60.</li>
<li>MultiMetaVerse Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMV#NASDAQ">MMV</a>) gained 24.2% to $0.61.</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) gained 23% to $14.02 after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates. Also, the company reported a year-over-year increase in quarterly daily active users.</li>
<li>Tutor Perini Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPC#NYSE">TPC</a>) surged 22.2% to $16.98 after the company reported better-than-expected first-quarter financial results and issued FY24 EPS guidance.</li>
<li>Sunshine Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) surged 22.2% to $0.9888.</li>
<li>U.S. Silica Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLCA#NYSE">SLCA</a>) gained 20% to $15.67 after the company reported first-quarter financial results and entered into a definitive agreement to be acquired by funds managed by affiliates of Apollo.</li>
<li>Earlyworks Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELWS#NASDAQ">ELWS</a>) rose 19.7% to $0.8725 after gaining 19% on Thursday.</li>
<li>Cullinan Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) surged 19.5% to $23.03.</li>
<li>Tevogen Bio Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares gained 19.3% to $1.0150 after falling over 43% on Thursday.</li>
<li>ATRenew Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RERE#NASDAQ">RERE</a>) surged 18.9% to $1.9150. ATRenew announced appointment of new director.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) gained 17.5% to $13.39.</li>
<li>Freight Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRGT#NASDAQ">FRGT</a>) climbed 17% to $1.0702 after gaining 5% on Thursday.</li>
<li>Skechers U.S.A., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) shares gained 16% to $68.20 after the company reported better-than-expected first-quarter FY24 earnings.</li>
<li>AppFolio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPF#NASDAQ">APPF</a>) surged 16% to $251.22 after the company reported better-than-expected first-quarter financial results and raised its FY24 revenue guidance above estimates.</li>
<li>Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) gained 15% to $7.97 after the company reported better than expected first-quarter earnings and issued guidance.</li>
<li>ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) shares rose 13.7% to $208.63 after the company reported better-than-expected third-quarter financial results.</li>
<li>Rogers Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROG#NYSE">ROG</a>) surged 12.7% to $123.46 after the company beat first-quarter EPS and sales estimates.</li>
<li>iLearningEngines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) gained 11.3% to $7.92</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) rose 10.6% to $172.52 the company posted upbeat results for its first quarter. Alphabet's board authorized an additional share repurchase program of up to $70 billion and also announced its first-ever quarterly dividend.</li>
<li>Kratos Defense &amp; Security Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) gained 8.8% to $18.80 after Raymond James upgraded the stock from Outperform to Strong Buy and raised its price target from $20 to $27.</li>
<li>AutoNation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) climbed 8.6% to $174.20 following second-quarter results.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) shares gained 8.4% to $0.8725 after gaining 15% on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>iClick Interactive Asia Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLK#NASDAQ">ICLK</a>) shares fell 48.8% to $1.31 after the company announced the termination of its merger agreement.</li>
<li>Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) fell 46.7% to $0.1540 after the company reported pricing of $2.7 million public offering.</li>
<li>Safe &amp; Green Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) fell 27.7% to $0.1584.</li>
<li>E-Home Household Service Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) dipped 25.3% to $0.5752.</li>
<li>Nature Wood Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWGL#NASDAQ">NWGL</a>) fell 24.5% to $12.71.</li>
<li>IMAC Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) dipped 22.9% to $3.93.</li>
<li>reAlpha Tech Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) fell 20.8% to $1.10.</li>
<li>ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) fell 19.3% to $4.84.</li>
<li>Saia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) dipped 19.1% to $439.40 after the company reported worse-than-expected first-quarter financial results.</li>
<li>Kinsale Capital Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) fell 17.3% to $374.29 following first-quarter results.</li>
<li>Aclarion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) fell 15.5% to $0.3319. Aclarion shares jumped 36% on Thursday after the company announced that its Nociscan solution will be used in the upcoming LIFEHAB trial evaluating the diagnosis and treatment of chronic low back pain.</li>
<li>Oil States International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIS#NYSE">OIS</a>) fell 15% to $4.5250 after the company reported worse-than-expected first-quarter financial results.</li>
<li>Boyd Gaming Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) shares declined 14.8% to $53.55 after the company reported worse-than-expected first-quarter adjusted EPS results.</li>
<li>Avenue Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) fell 13.5% to $7.59.</li>
<li>Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSSE#NASDAQ">CSSE</a>) fell 12.7% to $0.2260 after dipping 39% on Thursday. Chicken Soup For The Soul Entertainment received delinquency letter from the Nasdaq.</li>
<li>TriNet Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNET#NYSE">TNET</a>) fell 11.5% to $112.11 after the company reported worse-than-expected first-quarter results and issued weak guidance.</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares fell 11.1% to $31.23 after the company reported worse-than-expected first-quarter sales results and issued EPS guidance below estimates.</li>
<li>Accolade, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>) dipped 10.6% to $8.22 following quarterly results.</li>
<li>XPO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) fell 10.2% to $106.14.</li>
<li>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) shares fell 9.4% to $179.76 after the company reported third-quarter financial results. Atlassian said Scott Farquhar has decided to step down from his role as co-CEO, effective Aug. 31. Cannon-Brookes will continue to lead Atlassian as CEO.</li>
<li>Vincerx Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) shares fell 8.8% to $0.8180 after the company announced pricing of underwritten public offering of common stock and warrants.</li>
<li>SCWorx Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) fell 8.7% to $2.52 after surging 36% on Thursday.   </li>
<li>ACM Research, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACMR#NASDAQ">ACMR</a>) fell 8.3% to $25.94 after announcing preliminary unaudited revenue and shipments for the first quarter.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) shares fell 8.2% to $57.63 after the company reported first-quarter financial results.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) fell 7.8% to $2.52. Processa Pharmaceuticals shares jumped 50% on Thursday after HC Wainwright &amp; Co initiated coverage on the stock with a Buy rating and announced an $8 price target.</li>
<li>Red Rock Resorts, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) dipped 7.4% to $54.83.</li>
<li>ArcBest Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCB#NASDAQ">ARCB</a>) declined 7.3% to $128.07.</li>
<li>Allison Transmission Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>) fell 6.6% to $74.97 following first-quarter results.</li>
<li>Old Dominion Freight Line, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) fell 6.2% to $184.41.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) shares declined 6.3% to $129.17 after the company reported first-quarter financial results.</li>
<li>Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) fell 4% to $116.44 following weak earnings.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38459594/how-to-earn-500-a-month-from-dominos-pizza-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Domino&#8217;s Pizza Stock Ahead Of Q1 Earnings</a>

Intraday Update

Markets

Movers

ACCD

ACMR

ACON

AILE

AIRE

ALSN

APPF

ARCB

ATXI

BACK

BDRX

CGEM

CSSE

DXCM

ELWS

EXPO

FCUV

FRGT

GOOG

GOOGL

ICLK

INTC

KNSL

KTOS

Kintara Therapeutics, Inc. - Common Stock

KTRA

Eaton Vance Massachusetts Municipal Income Trust

NIVF

NUWE

NWGL

ODFL

PCSA

PEGY

RERE

ROKU

SAIA

SBFM

SGBX

SKIL

SLCA

TEAM

TNET

TVGN

VINC

WORX

ZVSA

Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Oppenheimer analyst Michael Wiederhorn maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Outperform and lowers the price target from $26 to $21.

TDOC

Oppenheimer Maintains Outperform on Teladoc Health, Lowers Price Target to $21

TD Cowen analyst Derrick Wood maintains Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Hold and lowers the price target from $220 to $210.

TD Cowen Maintains Hold on Atlassian, Lowers Price Target to $210

Oppenheimer analyst Owen Lau maintains S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) with a Outperform and raises the price target from $480 to $482.

SPGI

Oppenheimer Maintains Outperform on S&P Global, Raises Price Target to $482

Oppenheimer analyst Suraj Kalia maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Outperform and lowers the price target from $205 to $200.

Oppenheimer Maintains Outperform on ResMed, Lowers Price Target to $200

Oppenheimer analyst Bryan Blair maintains Dover (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>) with a Outperform and raises the price target from $187 to $197.

Oppenheimer Maintains Outperform on Dover, Raises Price Target to $197

PLTR

Palantir shares are trading higher as tech and AI stocks gain following strong earnings from Microsoft.

TD Cowen analyst Krish Sankar maintains KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) with a Hold and raises the price target from $650 to $700.

KLAC

TD Cowen Maintains Hold on KLA, Raises Price Target to $700

Oppenheimer analyst Noah Kaye maintains Carrier Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) with a Outperform and raises the price target from $63 to $64.

CARR

Oppenheimer Maintains Outperform on Carrier Global, Raises Price Target to $64

Oppenheimer analyst Bryan Blair maintains Carlisle Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>) with a Outperform and raises the price target from $412 to $430.

Oppenheimer Maintains Outperform on Carlisle Companies, Raises Price Target to $430

Oppenheimer analyst Ittai Kidron maintains Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Outperform and lowers the price target from $300 to $250.

Oppenheimer Maintains Outperform on Atlassian, Lowers Price Target to $250

TD Cowen analyst Matt Elkott maintains Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) with a Buy and raises the price target from $338 to $340.

TD Cowen Maintains Buy on Caterpillar, Raises Price Target to $340

<a href="https://www.wsj.com/business/media/paramount-considers-removing-ceo-bob-bakish-as-turmoil-over-sale-talks-deepens-a48b0ec5?mod=latest_headlines">https://www.wsj.com/business/media/paramount-considers-removing-ceo-bob-bakish-as-turmoil-over-sale-talks-deepens-a48b0ec5?mod=latest_headlines</a>
&nbsp;

PARA

'Paramount Considers Removing CEO Bob Bakish As Turmoil Over Sale Talks Deepens' - Wall Street Journal

Ideanomics Inc (IDEX) stock is down -92.69% over the last 12 months. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives IDEX stock a score of  2 out of a possible 100. That rank is mainly influenced by a long-term technical score of 3. IDEX's rank also includes a short-term technical score of 4.  IDEX has an Overall Sco

Is Ideanomics Inc (IDEX) Stock Worth a Buy Thursday?

Earnings week ahead: FedEx, Nike, XPeng, Tencent, General Mills and more

Earnings week ahead: Walgreens Boots Alliance, Carnival, GameStop and more

Notable earnings after Monday's close

Today, several major companies are expected to report earnings: Omeros (OMER), PVH (PVH), Sachem Capital (SACH), Ideanomics (IDEX), Sigma Lithium (...

Options Volatility and Implied Earnings Moves Today, April 01, 2024

This week, several major companies will be reporting earnings. Among them are BlackBerry (BB), Ideanomics (IDEX), Nano-X Imaging (NNOX), Levi Strau...

Options Volatility and Implied Earnings Moves This Week, April 01 – April 05, 2024

EV Company News For The Month Of March 2024

Ideanomics (IDEX) has provided an update. Ideanomics, Inc., a dynamic player in the financial sector, captivated investors with a compelling presen...

Ideanomics Unveils Strategic Insights and Financial Outlook

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
When building a stock portfolio, the most prudent strategy is typically to buy and hold shares of quality companies for the long haul. Avoiding businesses with flawed fundamentals or deteriorating financials can save you from getting stuck holding the bag on failing investments. However, I believe keeping a small portion of your portfolio for contrarian bets or speculative moonshot stocks can also prove rewarding, if done judiciously.



Of course , it&rsquo;s worth noting that these companies&rsquo; battered valuations could prompt massive short squeezes at any time. Savvy traders can still generate short-term gains by playing on their volatility. But make no mistake &ndash; the long-term investment merits of these companies seem dubious at best.



Ultimately, I advocate holding primarily mainstream, institutional-quality investments. Allocating a smaller amount to moon shot bets is great, but investors will want to focus the majority of their portfolio on companies with solid leadership and finances. 



So, for those looking to differentiate between the moonshot bets worth making, and the stocks I&rsquo;d put in the &ldquo;sell&rdquo; bucket, here are three of the latter.



<h2>Ideanomics (IDEX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/05/electric-vehicle-ev-stocks-charger-dark-sky-1600-300x169.jpg" alt="Two electric vehicles facing a dark sky, sunset background with one EV hooked up to an EV charger in between the two cars. EV Stocks"><div>Source: shutterstock.com/Larich</div></div>There&rsquo;s no sugarcoating it &ndash; the electric vehicle industry has endured a brutal year. High interest rates and recessionary fears decimated growth stock valuations, particularly those companies in the EV sector. Even innovative electric vehicle makers with promising futures have seen shares plunge dangerously close to penny stock territory. Ideanomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/idex-stock-quote/">IDEX</a>), a global EV solutions provider focused on fleet electrification, is one such beaten-down name facing extreme risks.



With losses mounting and cash reserves dwindling each quarter, it&rsquo;s tough to justify Ideanomics as a viable long-term investment any longer. In Q3 2023 alone, the company lost a staggering <a href="https://www.google.com/finance/quote/IDEX:NASDAQ">$63 million on just $5.4 million</a> of quarterly revenue. And its balance sheet now shows only around $2 million in cash remaining to fund near-term operations.



Make no mistake about it, the concept behind Ideanomics has merit. The company does have some strong tailwinds driving its valuation that could propel a move higher, if macro conditions improve. But in the current environment, raising capital is extremely difficult (and costly), making shareholder dilution seem inevitable just to keep the lights on.



<h2>AppTech Payments (APCX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/fintech_1600_1065252818-300x169.png" alt="Online banking businessman using smartphone with credit card Fintech and Blockchain concept"><div>Source: Joyseulay / Shutterstock.com</div></div>Unlike unprofitable and speculative <a href="https://investorplace.com/industries/consumer-discretionary/automotive/electric-vehicles/">EV stocks</a>, leading fintech disruptors tend to operate with attractive margin profiles, even in their early stages of growth. But as a relatively unknown fintech company targeting merchants and consumers, AppTech Payments (NASDAQ:<a href="https://investorplace.com/stock-quotes/apcx-stock-quote/">APCX</a>) is a clear outlier. Four consecutive quarters of mounting losses and less than $1.3 million in remaining cash paint the picture of a company racing towards dilution or insolvency, absent a drastic change in fortunes.



Bulls will rightfully point out that revenues grew double digits again in Q4 and annual losses narrowed slightly on an adjusted EBITDA basis. However, with AppTech still losing substantially more money each quarter than it generates in sales, its current run rate is untenable. And for a microcap fintech company to succeed, fast growth at high margins is paramount.



Perhaps AppTech can stage an unlikely turnaround in a few years and finally achieve cash flow breakeven. But its history and Q4 results argue otherwise. I&rsquo;m willing to bet AppTech won&rsquo;t have sufficient time to scale further before requiring another emergency cash infusion. Cutting losses seems to be a prudent strategy, as opposed to risking a total wipeout.



<h2>Stryve Foods (SNAX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/10/healthy-food-300x169.jpg" alt="BSFC Stock. Healthy food including salmon, almonds, garlic, broccoli, avocado, and lettuce"><div>Source: Shutterstock.com</div></div>In an environment where cash is king for small-cap companies, very few situations appear more dire right now than what we&rsquo;re seeing at Stryve Foods (NASDAQ:<a href="https://investorplace.com/stock-quotes/snax-stock-quote/">SNAX</a>). The emerging packaged snacks player has seen its revenues rapidly shrink <a href="https://www.google.com/finance/quote/SNAX:NASDAQ">from $30 million in 2022 to just $17.7 million</a> this past year. There is little evidence Stryve can stop its cash bleed without an immediate strategic shift.



Making matters worse, Stryve&rsquo;s balance sheet is saddled with nearly $24 million of highly-restrictive debt converting over the coming year which will effectively wipe out today&rsquo;s shareholders altogether. The company recently reported holding only $377,000 in cash.



In short, extreme dilution seems inevitable in the near-term, for Stryve to just to keep the lights on. That is, if debt holders don&rsquo;t seize control of the company entirely. I think SNAX stock will likely be rendered worthless or near-worthless sooner rather than later.



<a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a>



On Penny Stocks and Low-Volume Stocks:&nbsp;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&nbsp;<a href="http://investorplace.com/" target="_blank">InvestorPlace.com</a>&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&nbsp;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">How to Profit Without Getting Scammed</a>



On the date of publication, Omor Ibne Ehsan did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines.</a>
<div>Omor Ibne Ehsan is a writer at InvestorPlace. He is a self-taught investor with a focus on growth and cyclical stocks that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as cryptocurrencies and penny stocks. You can follow him on <a href="https://www.linkedin.com/in/omor-ibne-ehsan-56068022b/">LinkedIn</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/04/dont-be-left-holding-the-bag-3-stocks-stocks-to-sell-asap/">Don't Be Left Holding the Bag: 3 Stocks Stocks to Sell ASAP</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.